Eli Lilly's Trading Volume Surges 56.64% to 29.99 Billion, Ranks 20th in Market

On June 20, 2025, Eli Lilly's trading volume reached 29.99 billion, marking a 56.64% increase from the previous day, placing it 20th in the day's stock market rankings.

Eli Lilly's Alzheimer's drug, donanemab, marketed as Kisunla, is undergoing re-examination by the European Medicines Agency (EMA) following a request from the company. This process began on June 2, as indicated in the committee's monthly meeting.

Eli Lilly's stock experienced a decline after the United Kingdom's national health provider announced it would not cover the company's new Alzheimer's treatment. The decision was based on the assessment that the benefits of the injection did not justify its cost, as stated by the UK's National Institute for Health and Care Excellence. The drug, Kisunla, is notable for being the first to demonstrate the ability to slow the progression of Alzheimer's, but it is expensive and carries safety risks.

Eli Lilly's market for its Alzheimer's drug may be smaller than initially anticipated. While Medicaid in the US covers monthly injections, the European Union declined to approve the drug in May due to risks of brain swelling. Analysts expect the drug to generate $153.3 million in revenue for Lilly this year, a decrease from the $173.8 million consensus in March.